Disrupting the glaucoma treatment paradigm with novel femtosecond laser from ViaLase
Shawn O'Neil of ViaLase shares updates on the company's femtosecond laser, image-guided, high-precision trabeculotomy (FLigHT) treatment.
Trukera Medical rebranding ushers in new era of expansion into cornea market
Adam Szaronos, President and CEO of Trukera Medical, discusses the recent rebranding of TearLab as well as the launch of the ScoutPro Osmolarity System.
2-year data in contralateral eye evaluation gives edge to iStent inject over Hydrus stent
At AAO 2022, Dr Mitch Shultz provides discourse on iStent inject vs Hydrus contralateral eye evaluation data.
AAO recap: Clinical trial updates, new innovations presented at America's biggest ophthalmic conference
A combination of posters, podium presentations and instructional courses provided invaluable revelations to the ophthalmic community.
No negative effects in DMO patients reported following pandemic-imposed health care restrictions
The data analysis showed that the macular thickness decreased across all time periods and in all macular regions for all terciles.
Risk factors for developing rhegmatogenous retinal detachments in fellow eyes identified in study
Patients with a unilateral rhegmatogenous retinal detachment frequently ask about the risk of developing an RRD in their fellow eye.
Increased smoking-related ocular symptoms linked to cigarettes than electronic cigarettes
Those who used both traditional and electronic cigarettes reported severe to very severe ophthalmic symptoms.
Pooled TENAYA, LUCERNE Phase 3 data reports safety, efficacy, lower treatment burden with faricimab for nAMD
The AVONELLE-X long-term extension study will continue to evaluate the efficacy, durability and safety of faricimab in patients with neovascular AMD.
Younger patients often require repeat corneal crosslinking, study finds
At the 2022 American Academy of Ophthalmology meeting, Dr Philip Dockery, MPH, presents, "Effectiveness of corneal crosslinking in young patients."
Retinal detachment rates following acute retinal necrosis are unaffected by early treatment with antivirals, vitrectomy
The results also showed that, compared to use of systemic antivirals alone, treatment with adjunctive intravitreal injections or early pars plana vitrectomy did not affect the time to development of retinal detachments.
Is the robot-assisted procedure the future of MIGS?
Robot-assisted surgical precision offers less than 5-µm precision tremor stabilization, 1 to 10-mN force-sensing smart instrumentation and automated procedure-specific guidance and assistance with analytics.
Investigators report positive visual outcomes one year after monocular implantation of small aperture IOL
Dr Mark H. Blecher dives into his AAO 2022 topic: "One-Year Visual Outcomes Following Monocular Implantation with a Small Aperture IOL."
Fluid dynamics in wet macular degeneration: How fluid type affects visual acuity
At AAO 2022, Dr Justis Ehlers presented a talk entitled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"
Utilising AAO cornea preferred practice patterns for corneal oedema, opacifications, ectasia and bacterial keratitis
David Hutton discusses the AAO 2022 talk, "Corneal Oedema, Opacifications, Ectasia, and Bacterial Keratitis: Diagnosis and Treatment Strategies from the Preferred Practice Pattern Guidelines," with presenter Dr Francis S. Mah.
Comparing dry eye disease in adult and paediatric populations via the IRIS Registry
Almost 5 million patients in the IRIS Registry had received at least one diagnosis of DED between 2013 and 2019; of those, 203,171 were children under 18 years of age and 4,592,808 were adults.
Higher incidence of new strabismus in paediatric patients following tube shunt surgery
13% of pediatric patients had new-onset strabismus after a tube shunt procedure; in contrast, 0% of adults had new-onset strabismus after tube shunt surgery (at 6 months or at last follow-up).
Anti-VEGF therapy slows progression of severe NPDR in Monte Carlo simulation model
Dr Quan Dong Nguyen reviews a Monte Carlo simulation that showed evidence that treating severe NPDR with anti-VEGF therapy garners positive results.
Studying teprotumumab adherence in patients with thyroid eye disease
Dr Raymond Douglas discusses real-world adherence to teprotumumab as a treatment for thyroid eye disease.
VIVID/VISTA: How baseline factors affect DMO resolution
Dr Katherine Talcott discusses baseline factors—CST thickness, hemoglobin A1C, and baseline vision—and their effects on DMO resolution.
Corneal cross-linking and epithelial management: four pearls for success
Dr Preeya Gupta walks through her four pearls for successful corneal collagen cross-linking, including handling patient expectations, managing the epithelial cells and preventing infectious keratitis.
Dexamethasone insert reduces time spent planning cataract surgery, counselling patients
Dr Lisa Nijm discusses how utilising a dexamethasone intracanalicular insert after cataract surgery saves time for practices.
Phase 3 NORSE TWO proves ophthalmic bevacizumab effectively treats wet macular degeneration
Dr Firas Rahhal discusses Outlook Therapeutics’ Phase 3 pivotal NORSE TWO trial for ONS-5010.
Delving into ancillary testing frequency based on the IRIS registry
Dr Ted Leng discusses his presentation, “Variations in Vitreoretinal Physician Utilization of Ancillary Testing: An IRIS Registry Analysis” during Retina Specialty Day at AAO 2021.
Investigating best practices for MicroPulse transscleral therapy for glaucoma
Robert J. Noecker, MD, MBA, discusses the IRIDEX consensus paper regarding MicroPulse transscleral therapy for glaucoma at AAO 2021.
Bimatoprost implant successfully lowers IOP in Phase 3 of the ARTEMIS study
At AAO, AbbVie presented results from the ARTEMIS study, showcasing IOP lowering that extends beyond the original 20-month timeframe.
Updates on brolucizumab for treatment of wet AMD and DMO
Dr Jill Hopkins discusses results from phase 3a of the Merlin trial for brolucizumab as a treatment for wet AMD and provides updates on KESTREL and KITE trials for the treatment of diabetic macular oedema.
Shedding light on antibiotic resistance in ophthalmology with ARMOR study data
At the 2021 American Academy of Ophthalmology annual meeting, Dr Penny Asbell discussed data from the ARMOR study and its effects on treating ophthalmic infections, such as endophthalmitis.
Cell therapy for corneal endothelial disease proves successful in Japan, El Salvador
New cell therapy drug makes treatment of corneal endothelial disease more accessible.
Phase 1 study results for new sustained-release anti-VEGF formulation, EYP-1901
Dr Jay Duker discusses EYP-1901, EyePoint Pharmaceuticals’ sustained-release anti-VEGF drug for the treatment of wet AMD.
Phase 2b study results of AR-15512 for the treatment of dry eye
At AAO 2021, Aerie Pharmaceuticals presented the results of their phase 2b clinical trial of AR-15512, a TRPM8 antagonist, for the treatment of dry eye.
2 Clarke Drive Cranbury, NJ 08512